Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007112 (prostatic adenocarcinoma)
 2,574 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors reviewed the histologic slides of 2600 prostatic carcinomas seen at Memorial Hospital from 1963 to 1983. In ten cases, resection specimens had a predominantly endometrioid appearance. Six patients had polypoid lesions in and around the verumontanum, and one had a polypoid lesion away from the verumontanum. Two patients had no mucosal lesions and one was not cystoscoped. Histologically, the tumors showed a tall pseudostratified columnar epithelium, usually with amphophilic cytoplasm. The cells were arranged either along papillae or in complexes of large acini or in single glands. In eight of the ten cases, the endometrioid carcinomas were associated with a prior or coexistent typical microacinar prostatic adenocarcinoma. In four cases, the endometrioid pattern existed in a pure form, although in two such cases with urethral tumors, the patients had histories of successfully treated microacinar adenocarcinomas of the posterior prostatic lobe. In one case, a urethral endometrioid tumor coexisted with a small posterior lobe microacinar adenocarcinoma. In five cases, both endometrioid and microacinar carcinomas were seen, including endometrioid and microacinar carcinomas found at the same site at different times (2 cases), tumors with a predominantly endometrioid, yet focally microacinar pattern (1 case), and primary tumors where lymph node metastases had different histologic features (2 cases). Of the three patients with a pure or predominantly endometrioid pattern treated with diethylstilbestrol, two had a marked clinical response. All ten endometrioid prostatic adenocarcinomas showed prostate-specific antigen and prostate-specific acid phosphatase immunoreactivity, in contrast to none of the control uterine endometrial carcinomas. In material spanning a 20-year period, the authors have not seen a single prostatic tumor entirely analogous to the uterine endometrial carcinoma. Until such proof exists, prostatic carcinomas with endometrioid features are best classified and treated as variants of prostatic duct carcinomas.
 ...
PMID:Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. 241 22

A case of mucinous adenocarcinoma of the prostate that was diagnosed with the aid of prostate-specific antigen immunoperoxidase staining is reported. Focal areas of the tumor, which were morphologically similar to the remainder of the tumor, stained with neuron-specific enolase by an immunoperoxidase technique and with the Grimelius stain. This tumor is best thought of as a variant of the classic acinotubular adenocarcinoma of the prostate with well-differentiated cells that secrete mucin, rather than as a completely different type of cancer, as proposed previously.
 ...
PMID:Mucinous adenocarcinoma of the prostate. 242 79

Two cases of prostatic adenocarcinoma metastatic to the lung are presented. The prostatic origin of the metastatic carcinomas was confirmed by immunocytochemical demonstration of prostate-specific antigen and prostatic acid phosphatase in cellular samples obtained by fine needle aspiration of the pulmonary lesions.
 ...
PMID:Fine needle aspiration cytology of prostatic adenocarcinoma metastatic to the lung confirmed by the immunoperoxidase technique. 243 Mar 90

A rare case of urethral metastasis from prostatic adenocarcinoma is reported. Ordinary histological examination by hematoxylin and eosin staining could not determine whether the primary site was the prostate or the urethra. However, with an immunoperoxidase technique using prostate-specific acid phosphatase and prostate-specific antigen as markers for prostatic cells, we obtained a precise diagnosis of the primary sites. As a result, the patient could be successfully treated with hormonal therapy.
 ...
PMID:Urethral metastasis from prostatic carcinoma as diagnosed by immunoperoxidase technique using prostate-specific antigen and prostate-specific acid phosphatase. 243 38

The reactivity of the anti-Leu 7 monoclonal antibody (Leu 7) was tested on 83 human tumours and on non-neoplastic prostatic, hepatic and pancreatic tissues. A four-step peroxidase-anti-peroxidase method was used on paraffin embedded tissues and we observed strong cytoplasmic positivity in all 19 primary prostatic tumours, in two metastatic, poorly differentiated prostatic adenocarcinomas, and in normal and hypertrophic prostatic epithelium. All the primary prostatic tumours also stained positively for prostate-specific antigen and for prostatic acid phosphatase using polyclonal antisera. The degree of positivity for these antigens varied from case to case. Adenocarcinomas arising from the gastrointestinal tract, pancreas and gallbladder were anti-Leu 7 negative. Focal Leu 7 positivity, largely confined to cell membranes, was observed in some ovarian, endometrial, renal, lung and breast adenocarcinomas. These tumours, as well as some of the gastrointestinal, hepatic and pancreatic tumours, also showed focal cytoplasmic positivity for prostate-specific antigen and prostatic acid phosphatase. Our findings suggest that the anti-Leu 7 monoclonal antibody is a marker that may facilitate the detection of metastatic prostatic adenocarcinoma, especially when used in conjunction with staining for prostate-specific antigen.
 ...
PMID:Anti-Leu 7 immunoreactivity with human tumours: its value in the diagnosis of prostatic adenocarcinoma. 244 19

Prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels were measured in 117 patients with prostatic adenocarcinoma, in 9 patients with prostatic hyperplasia and in 14 patients with other malignancies to compare the clinical usefulness of the PSA and PAP levels. PSA was elevated (PSA+) in 14 of 18 untreated patients (78%) with prostatic cancer. PAP was elevated (PAP+) only in 3 of these untreated cases (17%). Also in previously treated patients PSA was more often positive than PAP. PSA was positive in 40 of the 99 treated patients (40%), PAP was elevated only in 21 cases (21%). There was a significantly (P less than 0.001) higher tendency towards elevated PSA in the prostatic cancer patients: 32 (27%) patients with PSA+ and PAP- compared with only 2 cases (2%) with PAP+ and PSA-. The PSA+/PAP- patients were analyzed further. In seven of them the PSA level also returned to its normal level after orchiectomy or/and radiotherapy. In two patients the PSA levels indicated tumor progression earlier than PAP, their PAP levels did not rise until bone metastasizing was evident. There were also progressive disease in some patients evidenced only by increased PSA levels. In addition to cancer patients the PSA level was increased in three (30%) of the prostatic hyperplasia patients. It was also elevated in three patients with other malignancies. However, these three patients also had prostatic hyperplasia and the increase in the PSA level is considered more likely to be due to that.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Prostate-specific antigen as a marker of adenocarcinoma of prostate. 247 59

Signet ring cell adenocarcinoma (SRCA) is an extremely rare tumor of the prostate. We document with histochemistry, immunohistochemistry, and electron microscopy an incidental "signet ring" cell adenocarcinoma of the prostate in a fifty-seven-year-old white male with chronic lymphocytic leukemia who died of an intracerebral hemorrhage. The signet ring cells stained weakly for neutral mucin and were strongly positive for both prostate-specific antigen and prostate acid phosphatase. In addition, electron microscopy demonstrated intracellular lumina with microvilli and cytoplasmic vacuoles of mucin. This case conclusively supports the existence of SRCA of the prostate.
 ...
PMID:Signet ring cell carcinoma of prostate. Immunohistochemical and ultrastructural study of a case. 247 83

An immunocytochemical method to localise prostate-specific antigen (PSA) in paraffin sections was used to establish the prostatic origin of both primary and metastatic tumours. The specificity of the technique was confirmed in 65 known primary (63 PSA-positive) and 17 metastatic prostatic carcinomas (16 PSA-positive). Thirteen non-prostatic primary carcinomas and a series of benign proliferative and malignant conditions which might be considered in the morphological differential diagnosis of prostatic adenocarcinoma were PSA-negative. The technique has now been applied diagnostically to tumour tissue resected from 21 patients. These neoplasms of the base and neck of the bladder could not be categorised as prostatic or urothelial in origin by clinical and endoscopic assessment or by conventional histopathology. In 11 patients such tumours were PSA-positive, indicating a prostatic origin. In two further patients, the prostatic origin of lymph node secondaries was confirmed in the absence of a clinically apparent primary. The technique is a valuable adjunct to conventional histopathology.
 ...
PMID:Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. 257 46

Tumor-to-tumor metastases are uncommon despite the fact that the presence of two or more malignancies in a single patient is not a rare occurrence. The most frequent donor tumors are the lung, prostate, and thyroid gland, whereas renal cell carcinoma is by far the most common recipient. In this report we describe a patient dying of metastatic malignant melanoma and locally advanced prostate cancer in which the melanoma metastasized to the prostatic adenocarcinoma. The prostatic primary was well differentiated and stained positively with prostate-specific antigen and prostatic acid phosphatase, whereas the melanoma contained abundant melanin pigment and stained positively for S-100 protein. This is the second reported instance of prostatic carcinoma as the recipient in a case of tumor-to-tumor metastases and the first in the English language literature.
 ...
PMID:Malignant melanoma with metastasis to adenocarcinoma of the prostate. 291 Apr 17

Cells of adenocarcinoma of the prostate (ACP) are infrequently shed in urine. We examined the clinicopathologic features of 22 patients with ACP and tumor cells in urine. Patients typically were clinical stage C or D and had hematuria (13 cases, 59%) and/or obstruction (11 cases, 50%). Prostatic palpation or instrumentation preceded collection of 15 urine specimens. Histologically, tumors were high grade (Gleason score 7-10) and extensive, with involvement of prostatic ducts and acini (10 cases, 45%) and prostatic urethra (5 cases, 23%). Cytologically, the background was clean, and neoplastic cells appeared singly, in loose clusters, as large "casts," or, rarely, in papillary structures. The cells were small, round to oval, with a moderate amount of finely granular or vacuolated cytoplasm; nuclei were generally round with a thin, often irregular membrane, finely granular chromatin, and a single prominent nucleolus. Immunoperoxidase staining for prostatic acid phosphatase and prostate-specific antigen was useful in distinguishing ACP from transitional cell carcinoma.
 ...
PMID:Cytologic features of prostatic adenocarcinoma in urine: a clinicopathologic and immunocytochemical study. 325 7


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>